Subject(s)
Breast Neoplasms , Breast Neoplasms/diagnosis , Female , Humans , Prognosis , Receptor, ErbB-2 , Receptors, ProgesteroneSubject(s)
Breast Neoplasms , Dimaprit/analogs & derivatives , Follow-Up Studies , Humans , Paclitaxel , Receptor, ErbB-2 , TrastuzumabSubject(s)
Breast Neoplasms/diagnostic imaging , Breast Neoplasms/pathology , Lymph Nodes/diagnostic imaging , Lymph Nodes/pathology , Clinical Trials as Topic/economics , Clinical Trials as Topic/methods , Female , Humans , Lymphatic Metastasis , Lymphoscintigraphy/economics , Lymphoscintigraphy/methods , Sentinel Lymph Node Biopsy/economics , Sentinel Lymph Node Biopsy/methodsSubject(s)
Breast Neoplasms , Mastectomy , Axilla , Chemotherapy, Adjuvant , Female , Humans , Neoadjuvant TherapyABSTRACT
Cardiac myxomas are rare tumors. Esophageal adenocarcinomas are common tumors of the gastrointestinal tract. Simultaneous occurrence of these tumors has not been reported. A 52-year-old gentleman presented to our hospital with dysphagia and was diagnosed with esophageal adenocarcinoma. Routine echocardiography discovered a cardiac tumor in the left atrium. The cardiac tumor was surgically removed and biopsy confirmed a myxoma. We removed the cardiac tumor as the first step and then initiated neoadjuvant chemotherapy. It is ideal to constitute a multidisciplinary team to decide on the course of treatment in such cases.
Subject(s)
Adenocarcinoma/pathology , Esophageal Neoplasms/pathology , Esophagogastric Junction/pathology , Heart Neoplasms/pathology , Myxoma/pathology , Neoplasms, Multiple Primary/pathology , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/therapy , Cardiac Surgical Procedures , Chemotherapy, Adjuvant , Echocardiography , Esophageal Neoplasms/diagnostic imaging , Esophageal Neoplasms/therapy , Esophagogastric Junction/diagnostic imaging , Heart Neoplasms/diagnostic imaging , Heart Neoplasms/surgery , Humans , Male , Middle Aged , Myxoma/diagnostic imaging , Myxoma/surgery , Neoadjuvant Therapy , Neoplasms, Multiple Primary/diagnostic imaging , Neoplasms, Multiple Primary/therapy , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
OBJECTIVE: To assess late clinical outcomes with image guided intensity modulated radiotherapy (IG- IMRT) in gynecological malignancies. PATIENTS AND METHODS: We have been practicing IG IMRT for gynecological malignancies since January 2009. Here we are presenting our experience with this modern technique at median follow up of 38 months. During whole treatment bladder filling protocol was followed. Both target volumes and critical structures were contoured according to RTOG guidelines. Dose prescribed to clinical target volume (postop bed and nodal volume) was 50.4 Gy in 28 fractions. Cone beam CT (CBCT) scans were taken to quantify the status of target volume and normal structures. RESULTS: 80 patients were evaluated and analyzed who were treated from January 2009 to December 2014. Median age of our patients was 56.5 years. Out of eighty, forty four patients (55%) were of carcinoma endometrium and the rest 36 (45%) were of carcinoma cervix. None of our patients experienced late grade 3 or 4 bladder toxicity. Although late grade 3 and 4 bowel and rectal toxicity was experienced by single patient. 2.5% patients developed local recurrence, 5% patient developed nodal with distant metastases and 6.25% only distant metastases. Three of our patients developed lung cancer as second primary during follow up. 76.2% atients are alive with regular follow up. CONCLUSIONS: Our study concluded that IG IMRT increases patient compliance and reduces long-term side effects in post-operative gynecological malignancies without compromising local-regional control, disease free survival and overall survival.